Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

You may be eligible if

• DISEASE CHARACTERISTICS:
• At high risk for ovarian cancer and meets criteria for 1 of the following:
• * Family history of at least 2 ovarian\*\* or breast cancers\* among the patient and first- or second-degree relatives in the same lineage
• * Multiple primary cancers in the same person may fulfill this requirement
• * Ashkenazi Jewish ethnicity AND 1 first-degree or 2 second-degree relatives with breast\* or ovarian\*\* cancer
• * Ashkenazi Jewish ethnicity AND had prior breast cancer\*
• * BRCA1/BRCA2 mutation probability \> 20% by BRCAPRO
• * Positive for BRCA1 or BRCA2 mutation
• * First- or second-degree relative with a BRCA1/BRCA2 mutation NOTE: \*At least 1 breast cancer must be premenopausal (diagnosed at age 50 or under if menopausal status unknown); ductal carcinoma in situ qualifies as breast cancer
• NOTE: \*\*In relatives, only ovarian epithelial cancer, fallopian tube cancer, and primary papillary serous cancer qualifies as ovarian cancer
• No prior or concurrent ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum
• * No clinical evidence of ovarian cancer by physical examination, CA 125 evaluation, and pelvic ultrasound
• PATIENT CHARACTERISTICS:
• Age
• 19 and over
• Performance status
• GOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• WBC \> 3,000/mm\^3
• Granulocyte count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• No hemophilia or other bleeding disorder
• No serious anemia
• Hepatic
• Transaminases normal
• Bilirubin normal
• Renal
• Creatinine clearance \> 80 mL/min OR
• Creatinine \< 2.0 mg/dL
• Pulmonary
• No emphysema
• Other
• Not pregnant or nursing
• No psychiatric or psychological condition that would preclude giving informed consent
• No concurrent untreated malignancy except nonmelanoma skin cancer
• No other medical condition that would preclude blood draws (e.g., chronic infectious disease)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• More than 3 months since prior adjuvant chemotherapy
• Endocrine therapy
• Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed
• Radiotherapy
• More than 3 months since prior adjuvant radiotherapy
• Surgery
• More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)
• No prior oophorectomy
• Other
• More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy
• No concurrent participation in other ovarian cancer early detection clinical trials